Turning science into business: An optimised alternative to antibodies
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. Optimer binders are engineered to overcome these problems.
52 
Let's personalize your content